Develops immunotherapies and vaccines for cancers and infectious diseases. Offers antibody cytokine fusion proteins to enhance immune response. Now — the numbers.
That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.
The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.
Average growth of 232% a year over the last 4 years. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
This company is not turning a profit, so the market is pricing its sales instead: 74.8× for every dollar of annual revenue.
Against companies in its own sector, it looks cheaper than 45% of them.
Analysts' average target sits 48% above today's price.
Executive selling isn’t always bad news; people sell for personal reasons too. Still, the thin buying side is worth noting.
The stock trades 30% below its peak. The market has trimmed its expectations for the company.
Over the last 4 years, sales grew about 232% a year on average.
Sales run at $113.3M a year. A small number, but proof the product has real buyers.
A loss of $351.4M against $113.3M in annual sales.
At the current pace of spending, the cash lasts less than a year. After that, the company needs to find new money.
On our five-subject report card, IBRX sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: IBRX is a high-risk stock — not yet profitable, and its future rides on its product catching on.
The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.
Analysts’ average target sits above today’s price, yet the valuation grade (45/100) says the stock isn’t cheap.